Last reviewed · How we verify
Cleocin T — Competitive Intelligence Brief
marketed
Lincosamide Antibacterial
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Cleocin T (CLINDAMYCIN PHOSPHATE) — Pfizer. Cleocin T works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cleocin T TARGET | CLINDAMYCIN PHOSPHATE | Pfizer | marketed | Lincosamide Antibacterial | 1972-01-01 | |
| Clindamycin 2-Palmitate | CLINDAMYCIN PALMITATE | Pfizer | marketed | Lincosamide Antibacterial | 1986-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Cleocin T · 9789057 · Formulation · US
- — Cleocin T · 11129896 · Method of Use · US
- — Cleocin T · 12303563 · Formulation · US
Sponsor landscape (Lincosamide Antibacterial class)
- Pfizer · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cleocin T CI watch — RSS
- Cleocin T CI watch — Atom
- Cleocin T CI watch — JSON
- Cleocin T alone — RSS
- Whole Lincosamide Antibacterial class — RSS
Cite this brief
Drug Landscape (2026). Cleocin T — Competitive Intelligence Brief. https://druglandscape.com/ci/clindamycin-phosphate. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab